Introduction to the main functions and indications of Inavolisib

Inavolisib (Inavolisib) is a new generation of PI3Kα selective inhibitor developed by Roche for the treatment of advanced breast cancer associated with PIK3CA mutations. The drug precisely inhibits the PI3Kα isoform in the tumor cell signaling pathway, thereby blocking the proliferation and metabolic abnormalities of tumor cells, providing a new targeted treatment option for patients with hormone receptor positive (HR+), HER2 negative and PIK3CA mutations. Compared with traditional PI3K inhibitors, inaliset shows advantages in selectivity, safety and tolerability, and is an important progress in the field of breast cancer treatment.

In terms of mechanism,The PI3K pathway plays a key role in cell growth, metabolism and survival. When the PIK3CA gene is mutated, the activity of PI3Kα enzyme is excessively enhanced, leading to the continued growth of tumor cells. Inalisate can specifically bind to PI3Kα mutants, inhibit its activity, block the downstream AKT/mTOR signaling pathway, and thereby reverse the growth advantage of cancer cells. This high specificity enables it to effectively inhibit tumor progression while minimizing the impact on normal tissues.

Clinically, inalised is often used in combination with fulvestrant (Fulvestrant) to treat patients with PIK3CA mutant breast cancer who have progressed after receiving endocrine therapy. This combination program aims to dually inhibit the hormonal signaling and metabolic signaling of tumor cells, thereby delaying the occurrence of drug resistance and improving progression-free survival. Studies have shown that inaliset can significantly improve the treatment response rate while maintaining better quality of life.

In addition to breast cancer, research is also exploring its application potential in other solid tumors driven by PIK3CA mutations, such as endometrial cancer, head and neck squamous cell carcinoma, etc., showing a wide range of anti-tumor possibilities. The innovation of its molecular design lies in improving the drug's affinity for mutant PI3Kα, while reducing non-specific inhibition of PI3Kβ, δ and other subtypes, reducing common side effects such as hyperglycemia and rash, and providing better safety guarantees for long-term treatment.

Reference materials:https://www.itovebi-hcp.com/